PMID- 16336606
OWN - NLM
STAT- MEDLINE
DCOM- 20060127
LR  - 20161020
IS  - 1120-8694 (Print)
IS  - 1120-8694 (Linking)
VI  - 18
IP  - 6
DP  - 2005
TI  - Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease 
      symptoms for patients on proton pump inhibitor therapy.
PG  - 370-3
AB  - While night-time symptoms of gastroesophageal reflux disease (GERD) are common, 
      considerable controversy exists regarding the use of histamine-2 receptor 
      antagonists (H2Ras) for night-time reflux control. Some studies have suggested 
      possible tolerance to H2RA while others have suggested that long-term efficacy of 
      gastric acid control can be maintained with night-time H2RA use. The aim of this 
      study was to identify if GERD patients have sustained symptom improvement with 
      long-term use of night-time H2RA. Records of 56 consecutive GERD patients on 
      twice daily proton pump inhibitor (PPI) and night-time H2RA therapy were 
      reviewed. During a phone interview patients were asked a 5-item questionnaire, 
      which included overall assessment of symptoms, night-time symptoms, sleep 
      disturbance, duration and frequency of therapy. Of the 56 patients, 39 (31 women, 
      mean age 56) completed the questionnaire (15 were not reached and 2 did not 
      recall enough information). All respondents had taken night-time H2RA for at 
      least 1 month (28/39 patients with > 6 months duration) with 33/39 patients 
      taking H2RAs every night. The addition of H2RA led to an improvement in overall 
      symptoms in 28/39 (72%) patients, improvement in night-time reflux symptoms in 
      25/34 (74%) patients and improvement of GERD-associated sleep disturbance in 
      18/27 (67%) patients. Five (13%) patients had stopped the H2RA on their own, 
      stating that its efficacy waned after 1 month. Our results suggest that the 
      majority of patients report persistent improvement in GERD symptoms from 
      night-time H2RA use and that possible clinically important tolerance to H2RAs 
      occurs in a small number of patients. Further prospective, placebo-controlled 
      studies may help confirm that there is a role for night-time H2RAs in GERD 
      symptom control.
FAU - Rackoff, A
AU  - Rackoff A
AD  - Digestive Diseases Center, Medical University of South Carolina, Charleston, 
      South Carolina 29425, USA. rackoff@musc.edu
FAU - Agrawal, A
AU  - Agrawal A
FAU - Hila, A
AU  - Hila A
FAU - Mainie, I
AU  - Mainie I
FAU - Tutuian, R
AU  - Tutuian R
FAU - Castell, D O
AU  - Castell DO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dis Esophagus
JT  - Diseases of the esophagus : official journal of the International Society for 
      Diseases of the Esophagus
JID - 8809160
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Histamine H2 Antagonists/*adverse effects
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - *Proton Pump Inhibitors
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2005/12/13 09:00
MHDA- 2006/01/28 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2006/01/28 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
AID - DES [pii]
AID - 10.1111/j.1442-2050.2005.00518.x [doi]
PST - ppublish
SO  - Dis Esophagus. 2005;18(6):370-3. doi: 10.1111/j.1442-2050.2005.00518.x.